Improving inhaler adherence is crucial, especially during winter when asthma symptoms can worsen. The first step is ensuring ...

Undoubtedly there exists a need to improve the care of and outcomes for children who are suffering from asthma. This blog ...

For many people suffering from asthma, the winter months and the colder air can trigger asthma symptoms and flare-ups, which ...

Montelukast does not appear to increase the risk for neuropsychiatric adverse events in children and adolescents, according to a study published in JAMA Pediatrics. Montelukast is a leukotriene ...

Medically reviewed by Daniel More, MD Many people with asthma as children go into long periods of remission, with infrequent ...

Blood tests for cyclic adenosine monophosphate may be a simple and useful option for diagnosing asthma and determining its ...

Kinaset Therapeutics, a clinical-stage biopharmaceutical company developing inhaled therapeutics to treat serious respiratory diseases, today announced that the United States Food and Drug ...

GSK announces depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 17:00 Hrs [IS ...

EMA accepts for review GSK’s MAA for depemokimab for use in asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 09:00 Hrs [IST] GSK plc announced ...

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications. The submitted ...

GSK plc (LSE/NYSE: GSK) today announced that new drug applications have been accepted for review by the China National Medical Products Administration and submitted to the Japanese Ministry of Health, ...

Authenticated data presented in the Respiratory Drugs market report is based on findings of extensive primary and secondary research ...